Tevogen Bio Partners with Yale in Regulatory Sciences Program Expansion
The Yale School of Public Health’s regulatory sciences program expansion builds on the current regulatory affairs track program, which focuses on the administrative, policy, and legal aspects of product regulation.
Tevogen Bio announced in a July 14, 2021 press release its support of the Yale School of Public Health’s regulatory sciences program expansion, providing students with professional training. This expanded program builds on the current regulatory affairs track in the Yale School of Public Health’s Master of Public Health program, which focuses on the administrative, policy, and legal aspects of product regulation.
Regulatory sciences on the other hand, focuses on the development of new tools, standards, and approaches to assess the safety, efficacy, quality, and performance of products made by pharmaceutical, biologic, and medical device organizations, in addition to other industries.
“Stakeholders are searching for talented and emerging leaders in regulatory science, but current educational programs are scarce,” said Sten H. Vermund, Dean of the Yale School of Public Health, in a press release. “With Tevogen Bio’s support, we have an opportunity to reimagine our program and to grow it into one that matriculates students who ultimately become national and international leaders in the field.”
Source: BusinessWire, Tevogen
Drug Shortages and Complying with FDA’s 21 CFR 211.110 Guidance
April 2nd 2025Susan J. Schniepp, distinguished fellow at Regulatory Compliance Associates, and Rona LeBlanc-Rivera, PhD, principal consultant, Regulatory Affairs at Regulatory Compliance Associates, answer some questions about FDA’s January 2025 21 CFR 211.110 guidance document.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
